TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms.

Proinflammatory cytokines such as TNFα are elevated in patients with myeloproliferative neoplasms (MPN), but their contribution to disease pathogenesis is unknown. Here we reveal a central role for TNFα in promoting clonal dominance of JAK2(V617F) expressing cells in MPN. We show that JAK2(V617F) kinase regulates TNFα expression in cell lines and primary MPN cells and TNFα expression is correlated with JAK2(V617F) allele burden. In clonogenic assays, normal controls show reduced colony formation in the presence of TNFα while colony formation by JAK2(V617F)-positive progenitor cells is resistant or stimulated by exposure to TNFα. Ectopic JAK2(V617F) expression confers TNFα resistance to normal murine progenitor cells and overcomes inherent TNFα hypersensitivity of Fanconi anemia complementation group C deficient progenitors. Lastly, absence of TNFα limits clonal expansion and attenuates disease in a murine model of JAK2(V617F)-positive MPN. Altogether our data are consistent with a model where JAK2(V617F) promotes clonal selection by conferring TNFα resistance to a preneoplastic TNFα sensitive cell, while simultaneously generating a TNFα-rich environment. Mutations that confer resistance to environmental stem cell stressors are a recognized mechanism of clonal selection and leukemogenesis in bone marrow failure syndromes and our data suggest that this mechanism is also critical to clonal selection in MPN.

[1]  Angela G. Fleischman,et al.  The stem cell fitness landscape and pathways of molecular leukemogenesis. , 2011, Frontiers in bioscience.

[2]  P. Campbell,et al.  JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia. , 2010, Blood.

[3]  Erin F. Simonds,et al.  Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. , 2010, Blood.

[4]  B. Druker,et al.  CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. , 2010, Blood.

[5]  Michael G. Kharas,et al.  Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. , 2010, Cancer cell.

[6]  Jane Yates,et al.  TLR8-dependent TNF-(alpha) overexpression in Fanconi anemia group C cells. , 2009, Blood.

[7]  Andrew Collins,et al.  JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms , 2009, Nature Genetics.

[8]  A. Tefferi,et al.  CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients , 2009, Leukemia.

[9]  O. Kilpivaara,et al.  JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science , 2008, Leukemia.

[10]  David A. Williams,et al.  TNF-α induces leukemic clonal evolution ex vivo in Fanconi anemia group C murine stem cells , 2007 .

[11]  D. Gilliland,et al.  TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations , 2007, Leukemia.

[12]  David A. Williams,et al.  References Subscriptions Permissions Email Alerts Inflammatory Reactive Oxygen Species-Mediated Hemopoietic Suppression in Fancc-Deficient Mice , 2013 .

[13]  David A. Williams,et al.  TNF-alpha induces leukemic clonal evolution ex vivo in Fanconi anemia group C murine stem cells. , 2007, The Journal of clinical investigation.

[14]  D. Gilliland,et al.  TG 101209 , a small molecule JAK 2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK 2 V 617 F and MPL W 515 L / K mutations , 2007 .

[15]  P. Campbell,et al.  The myeloproliferative disorders. , 2006, The New England journal of medicine.

[16]  B. Druker,et al.  Characterization of murine JAK2V617F-positive myeloproliferative disease. , 2006, Cancer research.

[17]  A. Tefferi Pathogenesis of myelofibrosis with myeloid metaplasia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  P. Campbell,et al.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders , 2005, The Lancet.

[19]  L. Sabatier,et al.  Tumor necrosis factor alpha induces senescence and chromosomal instability in human leukemic cells , 2004, Oncogene.

[20]  F. Rosselli,et al.  Abnormal lymphokine production: a novel feature of the genetic disease Fanconi anemia , 1992, Human Genetics.

[21]  V. Poggi,et al.  TNF-alpha and IFN-gamma are overexpressed in the bone marrow of Fanconi anemia patients and TNF-alpha suppresses erythropoiesis in vitro. , 2003, Blood.

[22]  B. Aggarwal Signalling pathways of the TNF superfamily: a double-edged sword , 2003, Nature Reviews Immunology.

[23]  I. Dybedal,et al.  Self-Renewal of Multipotent Long-Term Repopulating Hematopoietic Stem Cells Is Negatively Regulated by FAS and Tumor Necrosis Factor Receptor Activation , 2001, The Journal of experimental medicine.

[24]  I. Dybedal,et al.  Tumor necrosis factor (TNF)-mediated activation of the p55 TNF receptor negatively regulates maintenance of cycling reconstituting human hematopoietic stem cells. , 2001, Blood.

[25]  M. Lensch,et al.  Selective pressure as an essential force in molecular evolution of myeloid leukemic clones: a view from the window of Fanconi anemia , 1999, Leukemia.

[26]  M. Buchwald,et al.  Multiple inhibitory cytokines induce deregulated progenitor growth and apoptosis in hematopoietic cells from Fac-/- mice. , 1998, Blood.

[27]  F. Rosselli,et al.  Abnormal lymphokine production: a novel feature of the genetic disease Fanconi anemia. II. In vitro and in vivo spontaneous overproduction of tumor necrosis factor alpha. , 1994 .

[28]  N. Shahidi,et al.  Tumor necrosis factor‐α overproduction in Fanconi's anemia , 1993 .

[29]  Birnie Gd,et al.  The HL60 cell line: a model system for studying human myeloid cell differentiation. , 1988, The British journal of cancer. Supplement.

[30]  R. Ohno,et al.  Effect of recombinant human tumor necrosis factor on the colony growth of human leukemia progenitor cells and normal hematopoietic progenitor cells. , 1987, Blood.

[31]  D. Williams,et al.  The suppressive influences of human tumor necrosis factors on bone marrow hematopoietic progenitor cells from normal donors and patients with leukemia: synergism of tumor necrosis factor and interferon-gamma. , 1986, Journal of immunology.